Karla McCann, DO
Family Medicine · Ford City, PANPI 1730162538
Payments from drug & device makers
Across 135 payments — averaging $14.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$460
- GSK$345
- Pfizer$143
- Lilly USA, LLC$132
- Amgen$108
- Tactile Systems Technology Inc$74
- plus $738 from 23 others
What the payments were for
- Food & beverage$1,999100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 46 | $460 |
| GSK | 19 | $345 |
| Pfizer | 8 | $143 |
| Lilly USA, LLC | 8 | $132 |
| Amgen | 5 | $108 |
| Tactile Systems Technology Inc | 2 | $74 |
| AbbVie(2 entities) | 4 | $62 |
| Phathom Pharmaceuticals, Inc. | 3 | $60 |
| Boehringer Ingelheim | 4 | $59 |
| AstraZeneca | 4 | $58 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $52 |
| Sanofi-aventis U.S. LLC | 4 | $48 |
| Johnson & Johnson | 3 | $44 |
| Amarin Pharma, Inc. | 3 | $43 |
| Currax Pharmaceuticals LLC | 3 | $43 |
| Dexcom, Inc. | 2 | $36 |
| Supernus Pharmaceuticals, Inc. | 2 | $32 |
| Edwards Lifesciences | 1 | $25 |
| Novartis | 1 | $22 |
| Azurity Pharmaceuticals, Inc. | 1 | $19 |
| Exact Sciences | 1 | $19 |
| Mirum Pharmaceuticals, Inc. | 1 | $17 |
| Astellas Pharma US Inc | 1 | $16 |
| E.r. Squibb & Sons, L.L.C. | 1 | $15 |
| Daiichi Sankyo Inc. | 1 | $15 |
| Kowa Pharmaceuticals America, Inc. | 1 | $15 |
| Axsome Therapeutics, Inc. | 1 | $15 |
| Merck | 1 | $12 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $11 |
How this compares
$1,999 in reported general payments places this provider in the 75th percentile of 4,967 family medicine providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 176 | $209,092 |
| EliquisApixaban | 195 | $174,896 |
| TrulicityDulaglutide | 142 | $157,592 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 136 | $101,033 |
| XolairOmalizumab | 11 | $91,587 |
| JardianceEmpagliflozin | 77 | $69,401 |
| XareltoRivaroxaban | 95 | $66,861 |
| Xultophy 100-3.6Insulin Degludec/Liraglutide | 24 | $49,867 |
| JanuviaSitagliptin Phosphate | 38 | $31,012 |
| RybelsusSemaglutide | 26 | $27,691 |
| FarxigaDapagliflozin Propanediol | 20 | $26,096 |
| InvokanaCanagliflozin | 33 | $23,885 |
| Spiriva RespimatTiotropium Bromide | 46 | $23,289 |
| Tresiba Flextouch U-200Insulin Degludec | 26 | $21,757 |
| Breo ElliptaFluticasone/Vilanterol | 40 | $21,215 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Xultophy 100-3.6, Rybelsus | $460 | $286,649226 claims |
| PfizerEliquis, Premarin | $143 | $186,487228 claims |
| Lilly USA, LLCTrulicity | $132 | $157,592142 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $345 | $133,120200 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat, Tradjenta, Stiolto Respimat | $59 | $121,496153 claims |
| Johnson & JohnsonXarelto, Invokana | $44 | $90,746128 claims |
| AstraZenecaFarxiga, Brilinta | $58 | $33,10733 claims |
| MerckJanuvia | $12 | $31,01238 claims |
| AbbVieLinzess, Synthroid | $62 | $13,281179 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,967 family medicine providers in Pennsylvania.
Other family medicine in Ford City
- Kem YenalPhila$12.6M
- Marcy FleckerSmithfield$6.9M
- Tiffany PlutoScottdale$4.8M
- Bryce PalchickPittsburgh$4.7M
- Harris CohenHorsham$3.7M
- Shari RozenPittsburgh$2.9M
- Richard CookUniontown$2.1M
- Bruce GebhardtErie$2.1M
- Peter CognettiScranton$1.9M
- Bradley FoxErie$1.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.